Heparin - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment.

29 Nov 2009 Heparin (HP) inhibits pulmonary artery smooth muscle cell (PASMC) growth in vitro and vascular remodeling in vivo. Bârzu et al. (1994) suggested that the antiproliferative effect of HP on rat aortic smooth muscle cell in vitro diminishes with ... Read more...

Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes.

10 Oct 2009 BACKGROUND: To investigate clusters of Serratia marcescens (SM) bloodstream infections (BSIs) at health care facilities in several states and determine whether contaminated prefilled heparin and isotonic sodium chloride solution (hereinafter, ... Read more...

Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

27 Sep 2009 OBJECTIVES: We assessed the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute coronary syndromes (ACS). BACKGROUND: GIB is a potential hemorrhagic complication in patients with ACS treated with ... Read more...

Latest indexed articles for 'Heparin - Administration & dosage'

These are the very latest articles for this heading:

• Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. 29 Nov 2009
• Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes. 10 Oct 2009
• Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 27 Sep 2009
• Incidence and causes of heparin-induced skin lesions. 26 Sep 2009
• Expression of concern. 18 Sep 2009
• Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial. 30 Aug 2009
• Catheter-directed tissue plasminogen activator infusion and concurrent systemic anticoagulation with heparin to treat portal vein thrombosis post orthoptic liver transplantation. 25 Aug 2009
• Comparison of the effect of intra-arterial versus intravenous heparin on radial artery occlusion after transradial catheterization. 23 Aug 2009
• Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. 18 Aug 2009
• Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. 8 Aug 2009
• [Anesthetic management for a patient with anti-phospholipid antigen syndrome] 30 Jul 2009
• [Case of anosmia which appeared after anaphylactic shock due to intravenous heparin] 30 Jul 2009
• Subcutaneous heparin for prophylaxis of venous thromboembolism in deep brain stimulation surgery: evidence from a decision analysis. 30 Jul 2009
• Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. 30 Jul 2009
• Comparison of recombinant and plasma-derived antithrombin biodistribution in a rabbit model. 30 Jul 2009
• Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. 30 Jul 2009
• Thrombocytopenia and other hot topics. 30 Jul 2009
• Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. 30 Jul 2009
• HETRASE study--did heparin treatment benefit patients with ALI/ARDS? 30 Jul 2009
• Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes. 21 Jul 2009

See a longer list of these articles.

Technical information about 'Heparin'

Definition: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Registry Number: 9005-49-6

Descriptor UI: D006493

Alternative terms: Heparin; Heparinic Acid; Liquaemin; Sodium Heparin; Heparin, Sodium; Heparin Sodium; alpha-Heparin; alpha Heparin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Fibrinolytic Agents; Anticoagulants;

Tree Number: D09.698.373.400;

History Note: /therapeutic use was HEPARIN, THERAPEUTIC 1965